Literature DB >> 30830216

Evaluation of the Inclusion of Studies Identified by the FDA as Having Falsified Data in the Results of Meta-analyses: The Example of the Apixaban Trials.

Craig A Garmendia1, Liliana Nassar Gorra2, Ana Lucia Rodriguez3, Mary Jo Trepka2, Emir Veledar4, Purnima Madhivanan2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30830216      PMCID: PMC6450302          DOI: 10.1001/jamainternmed.2018.7661

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  3 in total

1.  Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature.

Authors:  Charles Seife
Journal:  JAMA Intern Med       Date:  2015-04       Impact factor: 21.873

2.  Research Misconduct in FDA-Regulated Clinical Trials: A Cross-sectional Analysis of Warning Letters and Disqualification Proceedings.

Authors:  Craig A Garmendia; Neera Bhansali; Purnima Madhivanan
Journal:  Ther Innov Regul Sci       Date:  2018-01-31       Impact factor: 1.778

Review 3.  Best evidence synthesis: an intelligent alternative to meta-analysis.

Authors:  R E Slavin
Journal:  J Clin Epidemiol       Date:  1995-01       Impact factor: 6.437

  3 in total
  3 in total

1.  Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study.

Authors:  Alma R Oskarsdottir; Brynja R Gudmundsdottir; Hulda M Jensdottir; Bjorn Flygenring; Ragnar Palsson; Pall T Onundarson
Journal:  Blood       Date:  2021-05-20       Impact factor: 22.113

2.  Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study.

Authors:  Behrad Behdarvand; Emily A Karanges; Lisa Bero
Journal:  BMJ Open       Date:  2019-08-20       Impact factor: 2.692

3.  From honest mistakes to fake news - approaches to correcting the scientific literature.

Authors:  Thomas Stamm
Journal:  Head Face Med       Date:  2020-04-03       Impact factor: 2.151

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.